1 Min Read
Oct 11 (Reuters) - Biocartis Group NV :
* Astrazeneca comparative study confirms best-in-class status of Idylla kras mutation detection technology Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.